NCT00121225View on ClinicalTrials.gov

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2013

Conditions
Ciliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaIris MelanomaUveal MelanomaRecurrent Intraocular MelanomaRecurrent MelanomaStage IV Melanoma
Interventions
DRUG

vorinostat

Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.

Trial Locations (5)

19046

Fox Chase Cancer Center, Rockledge

19111-2497

Fox Chase Cancer Center, Philadelphia

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | Biotech Hunter | Biotech Hunter